We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+11.73%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$154M
AUM Growth
-$321K
Cap. Flow
-$1.79M
Cap. Flow %
-1.16%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
5
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$684K
2
CYTK icon
Cytokinetics
CYTK
+$405K
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$369K
4
LNTH icon
Lantheus
LNTH
+$329K
5
AMRN
Amarin Corp
AMRN
+$45

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INVA icon
1
Innoviva
INVA
$1.61B
$56.6M 36.64%
2,816,022
– –
NBIX icon
2
Neurocrine Biosciences
NBIX
$18.4B
$38.1M 24.68%
303,151
-5,965
-2% -$684K
AMRN
3
Amarin Corp
AMRN
$293M
$20.2M 13.05%
1,242,527
-4
-0% -$45
CYTK icon
4
Cytokinetics
CYTK
$10.8B
$19.4M 12.59%
588,357
-11,643
-2% -$405K
IRWD icon
5
Ironwood Pharmaceuticals
IRWD
$626M
$11.4M 7.4%
15,919,435
-470,565
-3% -$369K
LNTH icon
6
Lantheus
LNTH
$6.68B
$7.88M 5.1%
96,251
-3,749
-4% -$329K
VOR icon
7
Vor Biopharma
VOR
$1.08B
$823K 0.53%
25,401
– –

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
PWA
Providence Wealth Advisors Frankfort, Illinois $157M AUM 29.27% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SR
Syntax Research Boca Raton, Florida $157M AUM 16.51% 1-Year Est. Return
BRWM
Blue Rock Wealth Management Winston-Salem, North Carolina $157M AUM 18.03% 1-Year Est. Return

Sarissa Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Sarissa Capital Management held 7 positions worth $154M, down 0.21% from $155M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2025: portfolio turnover was 0%. Sarissa Capital Management opened no new positions and made no exits, leaving the 7-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sarissa Capital Management's biggest Q2 2025 reduction was Neurocrine Biosciences, cutting an estimated $684K.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $154M portfolio in Q2 2025.
  • Sarissa Capital Management opened 0 new positions and closed 0 in Q2 2025.
  • Sarissa Capital Management's portfolio value fell 0.21% quarter-over-quarter to $154M.

Based on Sarissa Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.